WE CONDUCT RESEARCH ON THE ROLE OF MICROBES IN VARIOUS HUMAN CONDITIONS. OUR PRIMARY FOCUS IS THE MICROBIOTA WHICH INFLUENCES UROLOGICAL OUTCOMES.
Jeremy Burton holds the Miriam Burnett Chair in Urological Sciences and is the Deputy Director of the Canadian Centre for Human Microbiome and Probiotics based in the Lawson Health Research Institute. He is an Associate Professor in the Division of Urology, Department of Surgery and Department of Microbiology & Immunology at Western University.
B.Sc., M.Sc., Ph.D. Microbiology and Immunology, dBA, University of Otago, New Zealand
September 22, 2020
Ureteral Stent Microbiota Is Associated with Patient Comorbidities but Not Antibiotic Exposure
September 10, 2020
Using a Drosophila model, we show how a beneficial strain of oxalate-degrading bacteria can reduce the risk of kidney stones
June 10, 2020
CTV News piece: A team of researchers with Western University and the Lawson Health Research Institute were looking at whether the procedure could help treat non-alcoholic fatty liver disease (NAFLD), a type of liver disease caused by obesity.
May 24, 2020
A randomised control study part of Dr Lauren Craven's PhD work published in the American Journal of Gastroenterology
March 20, 2020
PROBIOTICS & MICROBIOTA IN UROLOGY
A opinion piece on the future of probiotics in Urology published at the American Urological Association AUA News. The future in this area is bright if some bold steps are taken.
Talking about our collaborative studies using Faecal Microbiota Transplant (FMT) in combination with immune therapies. Also in Forbes.
A story in the Toronto Star where we give comments on the merits of probiotics
GET IN TOUCH
London, ON, Canada